The shortage of research examining the impact of psychoeducational approaches on negative symptoms may partly reflect the use of study methods that favor the selection of patients with a high level of positive symptoms. That is, participants in family education and support studies typically enter the studies while they are inpatients in an acute exacerbation stage of their illness.
The protocol included full specification of the multiple-family group intervention in a treatment manual, extensive training, close supervision of experienced clinicians at the field site, and measures of patient outcomes. The primary symptom measures were collected monthly during the two-year period. The main hypothesis tested was that when the analysis controlled for baseline symptoms (using baseline scores as a covariate) and for whether a patient was taking an atypical antipsychotic, patients receiving the multiple-family group intervention would be more likely to have reduced negative symptom scores than those receiving standard care over the 12-month period.
The criteria for inclusion in the study were a diagnosis of schizophrenia or schizoaffective disorder according to
DSM-IV criteria (
+33), age between 18 and 45 years, enrollment for mental health services in a community outpatient facility (Spokane Mental Health), residence with the family of origin or in regular contact with the family, patient and family consent to participate, and minimum attendance by one family member for at least five face-to-face contacts. Patients with either a history of substance abuse or current substance abuse were not excluded.
+Table 1 presents demographic characteristics of the total sample, which included 63 outpatients receiving treatment at a large mental health center in Spokane, Washington. The mean age of the clients was 33 years. Most were Caucasian males who had been in and out of the hospital five times over ten years of illness. Two-thirds of the sample were on atypical antipsychotics at baseline.
Measures taken during baseline suggested that, on average, participants had very mild positive symptoms as measured by the Brief Psychiatric Rating Scale (BPRS) and slightly greater than mild negative symptoms as measured by the MSANS. Five items from the BPRS were used to measure positive symptoms. Possible total scores range from 5, indicating no symptoms, to 35, indicating severe symptoms. The five-item MSANS composite score measuring negative symptoms could range from 5, indicating no symptoms, to 25, indicating severe symptoms.
Local university and state institutional review boards approved the study. Participants were recruited in cohorts of 14 to 18 persons between February 1996 and March 1997 and randomly assigned by cohort to a treatment group after the diagnostic and baseline assessments. Medication status—atypical versus conventional antipsychotic—was stratified within each cohort so that an equal number of persons in the multiple-family group and the standard-care group were on atypical medications such as clozapine, risperidone, and olanzapine.
Standard care. The outpatients assigned randomly to standard care received the usual services provided to Spokane Mental Health clients. These services were delivered by a treatment team consisting of a case manager, nurse, psychiatrist, and social worker in a long-term track for persons with severe and persistent mental illness. They included medication management, case management, and, for some, therapeutic and rehabilitative services. The client's case management team provided clinical case management and out-of-facility services when they were needed. Rehabilitative services included a work-ordered day program, a social program on evenings and weekends, and a supported employment program.
Multiple-family group intervention. The multiple-family group treatment, which was superimposed on standard care, was designed to help families and patients improve their coping and illness management skills. This general strategy was derived from work previously reported by Goldstein and associates (
+1), Falloon and colleagues (
+2), Hogarty and coworkers (
+3), and Leff and associates (
+6).
Specific treatment interventions implemented by multiple-family group clinicians were designed to engage key members of the family; provide information about the biologic aspects of schizophrenia and the treatment process using a standardized videotape, lectures, and written guidelines for coping; intervene early in incipient relapse; provide ongoing support and formal clinical problem solving for at least two years; and expand the family's social network.
The two family clinicians who led the group were selected on the basis of interest, clinical skills, and educational level. One had a bachelor's degree, and the other a master's degree. Multiple-family group clinicians were expected to function as the family's educator and consultant, as a coleader of the multiple-family group treatment sessions, and as the principal liaison to the patient's case manager and other treatment team members.
The multiple-family group protocol began with the two family clinicians' each meeting separately with three or four families, without the patients' being present, for three weekly single-family sessions. These sessions started within several weeks to a month after the patient and family gave informed consent. The two clinicians, the principal investigator, and the project psychiatrist then presented an educational workshop for these six to eight families together, again without the patients. This presentation was modeled on the survival skills workshop developed by Anderson and colleagues (
+34).
Two weeks later, six families in the multiple-family group began to meet biweekly with the patients present, led by the two family clinicians. Meetings were organized around a formal problem-solving procedure designed to develop individualized coping methods; the problem-solving procedures were derived from suggestions by group members. The multiple-family group model has been described elsewhere (
+8).
+
Family clinician training and supervision
Each family clinician read the treatment manual and was trained by the clinical supervisors. Training and monitoring for fidelity to the model consisted of systematic review of videotapes by the study supervisors of all family-engagement sessions and every multiple-family group meeting throughout the study period. Supervision occurred weekly by telephone consultation and through additional annual on-site supervision visits. Although clinicians were not required to meet competency criteria, supervision was especially intense during the initial phases of each group. Two multiple-family group clinicians were assigned to each of the first four cohorts.
The Psychotic Disorders version of the Structured Clinical Interview for DSM-IV (SCID-PD) was completed after the patient gave informed consent. Experienced raters also rated positive and negative symptoms.
+
Positive and negative symptoms
The interviewers measured positive and negative symptoms monthly. The MSANS contains 30 items that assess alogia, affective blunting, asociality-anhedonia, avolition, and inattention (
+17). The raters participated in training sessions for rating accuracy and reliability. The BPRS contains 24 items assessing both positive and negative symptoms (
+35).
Data analysis was conducted in three stages. The first stage summarized descriptive characteristics of the participants and positive and negative symptoms. The second stage assessed the change in the sum of the five MSANS global ratings averaged over four successive three-month time frames during one year. The scores were analyzed using an analysis of covariance (ANCOVA), which assessed differences while controlling for baseline MSANS scores. Other factors in the analysis were medications (atypical versus conventional) and substance abuse (yes or no). The third stage analyzed group differences on each of the five individual negative symptoms. We also computed correlations between mean score for negative symptoms at one year, relapse (a rating of 4 or higher for one of the five psychotic items on the BPRS for two successive months), and outpatient service utilization (minutes per month).
This analysis was based on 42 participants who received treatment for the full 12 months. Of the 63 participants assessed at baseline, 54 were randomly assigned to the study groups and completed at least one postbaseline assessment. An additional 12 participants dropped out of the study during the first year—six from the multiple-family groups and six from standard care. The MSANS scores of the dropouts did not differ significantly from the scores of those who completed treatment. After the manuscript was submitted, we conducted analyses on a larger sample of six cohorts (N=83). An analysis of 70 participants who received at least six months of multiple-family group treatment (N=35) or standard care (N=35) showed a significant effect of group treatment (F=3.7, df=1,67, p=.05). Other analyses indicated that group differences were not detected among participants who received less than six months of standard care or multiple-family group treatment.
As shown in
+Table 1 the participants were in their early thirties and predominantly male. Approximately two- thirds were on atypical medications at study entry, and 48 percent met criteria for
DSM-IV-defined substance abuse disorder. Summed baseline scores on the five-item MSANS measure indicated that the groups did not differ in negative symptoms. Participants did not differ on any of the remaining variables shown in
+Table 1.
+Table 2 presents MSANS scores of the multiple-family group and the standard-care group at baseline and for the next 12 months. A mixed-design, repeated-measures ANCOVA with one covariate (baseline MSANS scores), three between factors (group by medication type by substance abuse), and one within factor (the four three-month blocks) was performed on the composite MSANS scores. This analysis yielded a significant effect of group treatment (F=6.1, df=1,39, p<.05), indicating that multiple-family group participants had reduced negative symptoms compared with standard-care participants. None of the other main effects or interactions were significant.
To obtain a more detailed look at the negative symptom components, identical analyses were conducted separately on the mean ratings for each of the five symptoms. Because these analyses were based on a single item, they were less reliable than the analysis on the composite measure, and although the results were consistent with the results of the composite measures, they were less robust. Marginally significant effects were observed on the avolition item (F=3.9, df=1,39, p=.05), the flattening item (F=.7, df=1,39, p=.10), the alogia item (F=2.6, df=1,39, p=.11), and the asociality items (F=2.2, df=1,39, p=.14). Inattention was clearly not affected.
Finally, the relationship of negative symptoms to relapse and service utilization was examined. Although no relationship was noted between negative symptoms and outpatient service use or total hospitalization days, the one-year mean score on negative symptoms was significantly associated with occurrence of relapse (r=.47, p<.00l).
As noted in the introduction, considerable evidence has been found that psychoeducational multiple-family groups are effective in reducing relapse and rehospitalization. Indeed, the inclusion of family education as a best practice in the Schizophrenia PORT Project (
+36) is an indication of the empirical support for this intervention. On the other hand, little support has been found for the efficacy and effectiveness of psychosocial interventions on the negative symptoms of schizophrenia.
The results of this study indicate that psychoeducational multiple-family groups contribute to the management of negative symptoms in schizophrenia. These results are consistent with those of two other psychosocial intervention studies. The first was by Halford and colleagues (
+12), which found significant improvement in negative symptoms and quality of life among chronic patients after participation in a non-family-based psychoeducational rehabilitation program. The second study, by McFarlane and associates (
+8), was of acutely psychotic inpatients from admission to discharge. Compared with patients who participated in a single-family format, those in multiple-family groups experienced a reduction in negative symptoms.
Although the results reported here indicate that the multiple-family group intervention was associated with reductions in negative symptom, no effect was found for either atypical medications or substance abuse status. The failure to find effects due to atypical medications is at variance with several studies that have reported such effects with clozapine (
+37) and risperidone (
+38); however, participants in the study reported here were stratified, not randomized, on this variable.
Several aspects of this study warrant comment. First, the results were observed in a large community mental health center that provided services under a capitated managed care contract, an increasingly common outpatient arrangement and financial context. Second, the originators of the treatment did not provide the multiple-family group intervention in our study. In this respect our study is methodologically similar to a recent investigation by Schooler and colleagues (
+39) and represents an important intermediate step between the development and delivery of a novel intervention and dissemination into routine treatment.
Although further research is needed to investigate the mechanisms of action, the observed improvements in negative symptoms may reflect the fact that family psychoeducation serves to broaden and enrich the social environment of consumers and families alike. Such an interpretation is consistent with the observation that negative symptoms are more common in nonstimulating settings and less severe after enrichment of the social environment (
+40). The interpretation is also congruent with the view that social factors have a central role in the genesis of negative symptoms (
+41).
Social skills training has been demonstrated to have a significant effect on a cluster of negative symptoms, including poor rapport, social avoidance, poor flow of conversation, and emotional withdrawal (
+1,
+42). The socialization component of the multiple-family group intervention provides consumers with repeated exposure to persons who model normal social interactions. As consumers experience increased levels of support within the group, their social engagement skills improve.
In addition, the content of the family guidelines, such as lowered expectations and clear communications, and the problem-solving format of the multiple-family group intervention may also contribute to reductions in negative symptoms. Educating participants about negative symptoms reduces the family's tendency to criticize the consumer, which in turn encourages social engagement. Further, the emphasis on setting realistic limits and clear communications contributes to maintaining a low-key environment with structure and stability. The predictable environment together with the graded-task assignments developed through problem solving could conceivably lead to improved activation and motivation among consumers, by providing more opportunities for success. As participants in standard care received as many outpatient service hours as participants in the multiple-family group intervention, we attribute the difference in results to the difference in the focus of treatment.
The impact of the multiple-family group intervention on negative symptoms might also be related to treatment adherence variables such as attendance and medication compliance. To examine this possibility further, we conducted additional analyses of the relationships between negative symptoms and treatment adherence over time. The analyses on attendance indicated that participants in multiple-family groups attended a mean±SD of 16±11 sessions. The correlation coefficients between attendance and MSANS scores (averaged over three-month intervals) indicated that attendance was associated with reduced negative symptoms. This effect increased over time; significance was attained at the ten- to 12-month interval (r=−.56, df=32, p<.01). Similar analyses of the relationship between medication compliance and negative symptoms showed nonsignificant trends in the expected direction.
Taken together, the data suggest that the mechanism of negative symptom reduction is directly related to the level of participation by consumers in multiple-family groups, presumably through direct exposure to social interactions and practice at social engagement and related skill development.
The effects observed here are clinically significant because negative symptoms often prevent patients with chronic schizophrenia from being actively involved in psychosocial rehabilitation and complicate the transition to independent living in the community (
+43). Such symptoms profoundly interfere with the social and vocational functioning so necessary for successful community living and are concurrently correlated with poor community functioning (
+43). In addition, recent studies have shown that negative symptoms are significantly associated with subjective quality of life (
+23,
+24). In the study reported here, negative symptoms were significantly correlated with the occurrence of relapse (r=.47, p<.01).
Although the research literature clearly indicates that control of negative symptoms should be a clinical priority, the quiet nature of these symptoms together with the current emphasis on managing health care costs brings with it the danger of according them second-class priority. Despite their significance, negative symptoms are not the "squeaky wheel" of schizophrenia. Consistent with this view, persons in the sample with high levels of negative symptoms did not receive any more outpatient service hours than did those who had low levels. Indeed, the correlation during the first year of the study between mean MSANS scores and total outpatient staff time was -.03.
Given that recent studies have shown that negative symptoms are significantly associated with subjective quality of life, it is reasonable to expect that multiple-family groups may improve quality of life, particularly in the social and family relations domain.
This research was supported by grant R01-MH-52259 from the National Institute of Mental health to the first author. The authors thank Lori Pinter for participation as a multifamily group clinician and supervisor and Bonnie Horen for supervision.